Evidence map›Paper›PMID 42883934›Full record

Observational studyInternational journal of molecular sciences2026

Alexis Morales-Ortiz, Luis Abel Quiñones, Sol Betzabeth Rondón-Simancas, Gustavo Paredes, Andrea Avendaño, Zaida Gonzalez, Haydee Chávez, Juan J Palomino-Jhong, María R Bendezú, Jorge A García and 12 more

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Alexis Morales-OrtizDepartment of Toxicology and Pharmacology, Faculty of Pharmacy and Bioanalysis, University of Los Andes, Mérida 5101, Venezuela.
Luis Abel QuiñonesLaboratory of Chemical Carcinogenesis and Pharmacogenetics, Department of Basic and Clinical Oncology, Faculty of Medicine, University of Chile, Santiago de Chile, Chile & Latin American Network for Implementation and Validation of Clinical Pharmacogenomics Guidelines (RELIVAF), Santiago 8350499, Chile.ORCID 0000-0002-7967-5320
Sol Betzabeth Rondón-SimancasNeurology Unit, Faculty of Medicine, University of Los Andes, Mérida 5101, Venezuela.ORCID 0009-0002-1000-1667
Gustavo ParedesNeurology Unit, Faculty of Medicine, University of Los Andes, Mérida 5101, Venezuela.
Andrea AvendañoMedical Genetics Unit, Department of Paediatrics and Child Care, Faculty of Medicine, University of Los Andes, Mérida 5101, Venezuela.
Zaida GonzalezDepartment of Toxicology and Pharmacology, Faculty of Pharmacy and Bioanalysis, University of Los Andes, Mérida 5101, Venezuela.ORCID 0009-0009-3637-9677
Haydee ChávezFaculty of Pharmacy and Biochemistry, San Luis Gonzaga National University, Ica 11001, Peru.ORCID 0000-0002-8717-4307
Juan J Palomino-JhongFaculty of Pharmacy and Biochemistry, San Luis Gonzaga National University, Ica 11001, Peru.
María R BendezúFaculty of Pharmacy and Biochemistry, San Luis Gonzaga National University, Ica 11001, Peru.
Jorge A GarcíaFaculty of Pharmacy and Biochemistry, San Luis Gonzaga National University, Ica 11001, Peru.
Elizabeth J Melgar-MerinoFaculty of Pharmacy and Biochemistry, San Luis Gonzaga National University, Ica 11001, Peru.
Pompeyo A Cuba-GarciaFaculty of Pharmacy and Biochemistry, San Luis Gonzaga National University, Ica 11001, Peru.
Doris Laos-AnchanteFaculty of Pharmacy and Biochemistry, San Luis Gonzaga National University, Ica 11001, Peru.
Paulina Eliades Yarasca-CarlosBiological Sciences Faculty, San Luis Gonzaga National University, Ica 11001, Peru.
José Santiago Almeida-GalindoFaculty of Human Medicine, San Luis Gonzaga National University, Ica 11001, Peru.
Ricardo Pariona-LlanosBiotechnology, Faculty of Environmental Engineering, University of Applied Sciences, Lima 15067, Peru.
Felipe L Ignacio-CconchoyInternal Medicine Department, Alberto Sabogal National Hospital, Sologuren, Callao 07000, Peru.
Alvaro E Maguiña-IgnacioCentre for Research in Molecular Pharmacology and 4P Medicine, Vice-Rectorate for Research, San Ignacio de Loyola University, La Molina, Lima 15024, Peru.ORCID 0009-0006-6577-4965
Berta Loja-HerreraCentre for Research in Molecular Pharmacology and 4P Medicine, Vice-Rectorate for Research, San Ignacio de Loyola University, La Molina, Lima 15024, Peru.
Richard Yaya-AraujoCentre for Research in Molecular Pharmacology and 4P Medicine, Vice-Rectorate for Research, San Ignacio de Loyola University, La Molina, Lima 15024, Peru.
Nelson M VarelaLaboratory of Chemical Carcinogenesis and Pharmacogenetics, Department of Basic and Clinical Oncology, Faculty of Medicine, University of Chile, Santiago de Chile, Chile & Latin American Network for Implementation and Validation of Clinical Pharmacogenomics Guidelines (RELIVAF), Santiago 8350499, Chile.ORCID 0000-0002-5229-3007
Angel T AlvaradoCentre for Research in Molecular Pharmacology and 4P Medicine, Vice-Rectorate for Research, San Ignacio de Loyola University, La Molina, Lima 15024, Peru.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epilepsy is a chronic neurological disorder with a high global prevalence. In Venezuela, the limited availability of epidemiological and pharmacogenetic data represents an important public health challenge. Antiseizure medications (ASMs) are frequently associated with adverse drug reactions (ADRs), which may be influenced by genetic variability in drug-metabolising enzymes. This study evaluated the association between the

Indexed as

AnticonvulsantsCytochrome P-450 CYP2C9Drug-Related Side Effects and Adverse ReactionsEpilepsyPharmacogenomic VariantsAdolescentAdultAllelesCross-Sectional StudiesFemaleGene FrequencyGenotypeHumansMaleMiddle AgedVenezuelaAnticonvulsantsCYP2C9 protein, humanCytochrome P-450 CYP2C9adverse drug reactionsantiseizure medicationCYP2C9pharmacogeneticsVenezuelan patients

Identifiers

PMID42883934
PMCPMC13665442

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.